Skip to main content
. 2014 Apr 23;112(2):393–410. doi: 10.1152/jn.00647.2013

Table 1.

Effect of manipulating, experimentally and computationally, subthreshold conductances on resting membrane potential of TC neurons

Experiment
Model
RMP
RMP
Current Treatment Before Aftera Reference Treatment Before After
IKleak 1 mM MCh (300 nM TTX) −68.6 ± 2.5 −55.0 ± 2.5b Present study Turn off IKleak −69.7 −59.3
250 μM MCh 12 ± 6 mV depolarization Varela and Sherman 2007 Turn off IKleakc −71.5 −62.3
INaleak Turn off INaleak −69.7 −77.6
Ih 10 μM ZD-7288 −71.1 ± 2.4 −78.3 ± 1.7d Present study Turn off Ih −69.7 −77.9
100 μM ZD-7288 −71.0 ± 1.0 −79.0 ± 2.0 Meuth et al. 2006
HCN2 KO −69.0 ± 1.0 −81.0 ± 1.0 Meuth et al. 2006
−68.0 ± 1.0 −80.0 ± 1.0 Ludwig et al. 2003
INaP 300 nM TTX −71.0 ± 1.5 −71.9 ± 1.6e Present study Turn off INaPf −69.7 −71.5
IKir 50 μM Ba2+ −69.0 ± 1.1 −66.5 ± 0.9g Present study
Kir2.2 KO −69.3 ± 0.7 −66.8 ± 0.8h Present study Turn off IKir −69.7 −68.6
IT 1-3 μM TTA-P2 3.1 ± 0.5 mV hyperpolarization Dreyfus et al. 2010 Turn off IT −69.7 −72.3
IA Turn off IA −69.7 −57.2

Values are resting membrane potential (RMP; ±SE) in experimental or model-simulated thalamocortical (TC) neurons.

a

Comparison between wild type and knockout (KO) genotypes in the case of genetic elimination of HCN2 or Kir2.2.

b

Comparison of RMP before and after application of 1 mM β-methylcholine (MCh) in the presence of 300 nM TTX (n = 7; paired t-test, P = 0.00003).

c

Comparison of RMP before and after IKleak is turned off, with the sodium conductances previously switched off.

d

Comparison of RMP before and after application of 10 μM ZD-7288 (n = 10; paired t-test, P = 0.0004).

e

Comparison of RMP before and after application of 300 nM TTX (n = 18; paired t-test, P = 0.003).

f

Concomitantly turning off INaP and INa produces similar results.

g

Comparison of RMP before and after application of 50 μM Ba2+ (n = 17; paired t-test, P = 0.001).

h

Comparison between wild type (n = 66) and Kir2.2 KO (n = 19; 2-sample t-test, P = 0.02). TTA-P2, 3,5-dichloro-N-[1-(2,2-dimethyl-tetrahydropyran-4-ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide. See text for current definitions.

HHS Vulnerability Disclosure